Blood
Articles in this Issue
First-in-human Phase I study of autologous CD5-knockout anti-CD5 CAR-T cells in CD5⁺ hematologic malignancies
Abstract Introduction CD5 is broadly expressed across hematologic malignancies, notably in ~85% of T-cell tumors and is associated with poor...
Real-world experience in the first-line treatment of Acute Myeloid Leukemia with ven-aza: Optimizing venetoclax exposure for better outcomes
Abstract Introduction: First-line treatment of acute myeloid leukemia (AML) with venetoclax and azacytidine (VenAza) is both effective and s...
Real-world breakthrough hemolysis patterns across 1,723 patient-years of complement inhibition in paroxysmal nocturnal hemoglobinuria
Abstract Despite the introduction of specific treatment, some patients with paroxysmal nocturnal hemoglobinuria (PNH) will still experience...
Post-FDA approval experience with momelotinib in JAK inhibitor-naïve myelofibrosis: Focus on anemia response and treatment-emergent nephropathy and peripheral neuropathy
Abstract Background Momelotinib, a small-molecule Janus kinase 1 and 2 (JAK1/2) inhibitor (JAKi), is FDA-approved (September 15, 2023) for us...
PPPR15A, a stress response gene is upregulated in malignant myeloid progenitors in AML and higher risk MDS.
Abstract Introduction: Acute myeloid leukemia (AML) is an aggressive blood cancer driven by rapid immature myeloid cell proliferation and ge...
Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis
Abstract Background B-cell maturation antigen (BCMA)-targeting immunotherapies represent a promising class of treatment for the management o...
A multi-center study of a machine learning algorithm for identifying undiagnosed patients with myelodysplastic syndrome based on complete blood count data
Abstract Introduction: Myelodysplastic syndromes (МDS) are a heterogeneous group of hematologic neoplasms often asymptomatic in early stages...
Comprehensive classification of hematological malignancies by integrating genomic and immune repertoire profiles with explainable AI
Abstract Background: Accurate classification of hematologic malignancies remains challenging due to overlapping morphological, immunophenoty...
Examining the role of U2AF1 and TET2 mutations in a myeloid malignancy mouse model
Abstract Splicing factors (SFs) are among the most commonly mutated genes in MDS and are often associated with poor clinical outcome, along...
An automated platform for lentiviral transduction for HSC gene therapy promotes fitness of hematopoietic stem cells combined with higher transduction efficiency
Abstract Although therapies for HSC gene therapy have been recently approved (Zynteglo™, Lyfgenia™ and Casgevy®), still certain challenges r...
Real-world treatment patterns & outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the real-AVA 3.5 study
Abstract In the management of immune thrombocytopenia (ITP), an autoimmune disorder characterized by low platelet counts (PCs) and an increa...
Detection of intratumoral microorganisms in CTCL and patients symptoms and outcomes.
Abstract Detection of Intratumoral microorganisms in CTCL and patients symptoms and outcomes. Introduction: In CTCL the tumor microenvironme...
AI-based analysis reveals novel blood protein biomarkers for predicting cardiac amyloidosis approximately a decade early: A UK biobank study
Abstract Background: Amyloidosis are a complex debilitating group of diseases characterised by the extracellular deposition of abnormal amyl...
Using iPSC-derived hematopoietic stem cells with long-term engraftment capability to model fetal blood disorders
Abstract Introduction: Human developmental hematopoiesis is a complex process occurring in sequential waves at different embryonic sites. Thi...
Dynamic roles of hematopoietic notch signaling in extramedullary hematopoiesis
Abstract During embryonic development, hematopoietic stem cells (HSC) in the fetal liver undergo expansion and self-renewal. Fetal HSCs migr...
Improved overall survival in patients with advanced systemic mastocytosis treated with avapritinib versus real-world therapy based on mutation-adjusted risk score (MARS) stratification
Abstract Introduction Avapritinib (Ava) is a potent, selective KIT D816V inhibitor indicated for adult patients (pts) with advanced systemic...
Real-world outcomes with teclistamab in relapsed/refractory multiple myeloma and severe renal failure: A propensity matched multi-center retrospective study using trinetx database
Abstract Introduction: Teclistamab gained approval for relapsed/refractory Multiple Myeloma (RRMM) in late 2022; however...
Feasibility assessment of indirect treatment comparison between off-label rituximab and novel treatments in patients with warm autoimmune hemolytic anemia
Abstract Introduction: Indirect treatment comparisons (ITCs) provide valuable evidence on comparative efficacy where head-to-head clinical t...
Metabolic reprogramming by itaconate: Haescs-derived therapy targets fibroblast GLUD1 to alleviate ocular graft versus host disease
Abstract Backgroud：Ocular chronic graft-versus-host disease (ocGVHD) is a significant complication following allogeneic hematopoietic stem...
First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation
Abstract INTRODUCTION 35C is an investigational antibody-drug conjugate (ADC) comprising a chimeric immunoglobulin G1 CD30-directed monoclona...
A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy
Abstract Introduction Despite azacitidine and venetoclax (AZA/VEN) being a new standard treatment for newly diagnosed older/unfit AML, overa...
High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma.
Abstract Introduction Multiple myeloma is a malignant plasma cell dyscrasia traditionally managed with high-dose chemotherapy followed by au...
Characterizing benign ethnic neutropenia using a real-world national model: Evidence from national health and nutrition examination survey 2015–2018
Abstract Introduction: Benign Ethnic Neutropenia (BEN) is a physiologically distinct hematologic phenotype characterized by chronically redu...
Genomic characterization uncovers molecular subtypes in Mantle Cell Lymphoma
Abstract Introduction Mantle cell lymphoma (MCL) is a heterogeneous B-cell malignancy with variable prognosis, often driven by genetic altera...
Development of clinical manifestations in antiphospholipid antibodies carriers according to the 2023 acr/EULAR serological domains
Abstract INTRODUCTION Antiphospholipid syndrome (APS) is a thrombophilic disorder defined by thrombotic/obstetric events and persistent anti...